PV Bulletin

Updated eCTD v4.0 technical validation criteria

Revision of technical validation rules for eCTD v4.0 submissions impacting PSURs, RMPs, and other safety-related filings.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Revised technical validation rules for eCTD v4.0 submissions, requiring compliance for PSURs, RMPs, and other related filings.

Why it matters

These updates are critical for ensuring the accuracy and compliance of electronic submissions, impacting regulatory processes across the EU.

Action needed

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country ComplianceICSR
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Technical Guidance
Policy status
Revised
Publication date
2026-07-15
Policy change
Revision of technical validation rules for eCTD v4.0 submissions, which applies to PSURs, RMPs, and other safety-related filings.

Key changes

New validation checks and bug fixes for v4.0 electronic submissions.

Affected workflows

Country ComplianceICSR

PV impact

Requires technical alignment of electronic PV submissions (PSUR/RMP) with the updated validation criteria.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jul 15, 2026

Full briefing

Practical implication

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

The European Medicines Agency has revised the technical validation criteria for eCTD v4.0 submissions, introducing new validation checks and bug fixes. This change necessitates that electronic pharmacovigilance submissions, including Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs), align with the updated validation criteria.

What changed: Revised technical validation rules for eCTD v4.0 submissions, requiring compliance for PSURs, RMPs, and other related filings.

Why it matters: These updates are critical for ensuring the accuracy and compliance of electronic submissions, impacting regulatory processes across the EU.

Practical implication: All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Technical Guidance#Revised#European Medicines Agency (EMA)#reporting_requirement#policy-change#firecrawl-policy-agent

Related updates for your role

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward
publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Urgency: High

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward